Chinese and New Zealand research and publishing institutions to jointly launch academic journal "Cancer+"

On the morning of January 21, the signing ceremony of the Medical Immunodiagnosis Research Center of the Institute of Biophysics of the Chinese Academy of Sciences and Singapore WHIOCE Publishing House jointly founded an academic journal was held in Fangshan District, Beijing. The two sides will jointly establish an English academic journal "Cancer+" in 2019, with the first editor-in-chief Dr. Li Chong.


Liao Chunying, Vice President of Fangshan District Government of Beijing, attended the signing ceremony. Liao Chunying, Vice President of Fangshan District Government, spoke highly of the "Cancer+" jointly established by the Institute of Biophysics of the Chinese Academy of Sciences and WHIOCE Publishing House of Singapore. He welcomed and congratulated the signing ceremony held in Fangshan District. This activity has played a positive role in promoting Chinese academics to go global and enhancing the internationalization of Chinese academics. The signing ceremony was also supported by the professional community of bladder cancer "Gu Yu Society", and representatives of Singapore Nanyang Academy of Sciences and Malaysia Eno Institute in Beijing attended and congratulated.


Dr. Li Chong, Director of Medical Immune Diagnosis Research Center, Institute of Biophysics, Chinese Academy of Sciences, editor-in-chief of "Cancer+" journal, Wang Yutao, chairman of Best International, Li Xiaofan, Vice president of WHIOC Publishing House, Mo Yaohui, member of the Foreign Experts Database of The State Council, and some members of the editorial committee of "Cancer+" attended the signing ceremony. At the signing ceremony, Li Chong and Wang Yutao jointly signed the joint founding cooperation agreement, and Chairman Wang Yutao also awarded the editor-in-chief certificate to Mr. Li Chong, the first editor-in-chief of "Cancer+".


Li Chong said in his chief editor's speech that the excellent results achieved by the Medical Immune Diagnosis Research Center of the Institute of Biophysics of the Chinese Academy of Sciences and Singapore WHIOCE Publishing House in their respective academic activities have formed complementary advantages, which will bring congenital advantages to the founding of the new journal. Cancer+ is an international journal dedicated to the latest scientific research in the field of cancer. Its mission is to provide a forum for cancer researchers around the world to exchange research results and ideas, and to contribute to the promotion of interdisciplinary research and collaboration.


Mr. Li Xiaofan, Vice president of WHIOC Press, said in his speech that the quality and quantity of scientific research in China has ranked second in the world, and the importance of international scientific research is self-evident, and the comprehensive research institution such as the Institute of Biophysics of the Chinese Academy of Sciences has an important influence in the research field at home and abroad to launch "Cancer+". It is bound to vigorously promote the basic and applied research of cancer medicine in China and the world, and promote the transformation of medical diagnostic reagents in China and even the world with the help of the industry-university-research collaborative development experience of the Medical Immunodiagnosis Research Center of the Institute of Biophysics of the Chinese Academy of Sciences.


Chairman Wang Yutao mentioned that WHIOCE Press, based on the development orientation of global scientific publishing, will strive to provide publishing support for the majority of scientists. This is also the first cooperation between WHIOCE Press and the Medical ImmunoDiagnosis Research Center of the Institute of Biophysics of the Chinese Academy of Sciences in publishing. It is hoped that this successful cooperation can promote exchanges and cooperation between the two sides in more fields in the future, and both sides will give full play to their respective advantages and contribute their strength to international cancer research and Chinese academia going global.